November 28th 2023
Paying in installments with adjustments according to how well a gene therapy works is one way payers are coping with therapies with list prices in millions of dollars.
Gene Therapy for Rare Immune Disorder Gets FDA Review Date
October 25th 2023RP-L201 (marnetegragene autotemcel) is a one-time gene therapy that delivers a functional copy of the ITGB2 gene, which provides instructions for immune response to infections. The Prescription Drug User Fee Act (PDUFA) target action date is March 31, 2024.
Read More